CSS Drop Down Menu by

Publications → Papers → References

New mammalian target of rapamycin (mTOR) modulators derived from natural product databases and marine extracts by using molecular docking techniques. Ruiz-Torres, V., Losada-Echeberría, M., Herranz-López, M., Barrajón-Catalán, E., Galiano, V., Micol, V. and Antonio Encinar, J.A. 2018. Marine Drugs.

  1. Chiarini, F.; Evangelisti, C.; McCubrey, J. A.; Martelli, A. M., Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 2015, 36, (2), 124-35.
  2. Yang, H.; Rudge, D. G.; Koos, J. D.; Vaidialingam, B.; Yang, H. J.; Pavletich, N. P., mTOR kinase structure, mechanism and regulation. Nature 2013, 497, (7448), 217-23.
  3. Hara, K.; Maruki, Y.; Long, X.; Yoshino, K.-i.; Oshiro, N.; Hidayat, S.; Tokunaga, C.; Avruch, J.; Yonezawa, K., Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action. Cell 2002, 110, (2), 177-189.
  4. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, (5712), 1098-101.
  5. Ieranò, C.; Santagata, S.; Napolitano, M.; Guardia, F.; Grimaldi, A.; Antignani, E.; Botti, G.; Consales, C.; Riccio, A.; Nanayakkara, M.; Barone, M. V.; Caraglia, M.; Scala, S., CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death &Amp; Disease 2014, 5, e1310.
  6. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773, (8), 1263-84.
  7. Laplante, M.; Sabatini, David M., mTOR Signaling in Growth Control and Disease. Cell 2012, 149, (2), 274-293.
  8. Inoki, K.; Ouyang, H.; Zhu, T.; Lindvall, C.; Wang, Y.; Zhang, X.; Yang, Q.; Bennett, C.; Harada, Y.; Stankunas, K.; Wang, C. Y.; He, X.; MacDougald, O. A.; You, M.; Williams, B. O.; Guan, K. L., TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126, (5), 955-68.
  9. Anastasiou, D., Tumour microenvironment factors shaping the cancer metabolism landscape. British Journal Of Cancer 2016, 116, 277.
  10. Balgi, A. D.; Diering, G. H.; Donohue, E.; Lam, K. K.; Fonseca, B. D.; Zimmerman, C.; Numata, M.; Roberge, M., Regulation of mTORC1 signaling by pH. PLoS One 2011, 6, (6), e21549.
  11. Arsham, A. M.; Howell, J. J.; Simon, M. C., A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003, 278, (32), 29655-60.
  12. Cho, J. H.; Han, J. S., Phospholipase D and Its Essential Role in Cancer. Mol Cells 2017, 40, (11), 805-813.
  13. Yoon, M. S.; Rosenberger, C. L.; Wu, C.; Truong, N.; Sweedler, J. V.; Chen, J., Rapid mitogenic regulation of the mTORC1 inhibitor, DEPTOR, by phosphatidic acid. Mol Cell 2015, 58, (3), 549-56.
  14. Thoreen, C. C.; Chantranupong, L.; Keys, H. R.; Wang, T.; Gray, N. S.; Sabatini, D. M., A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012, 485, 109.
  15. Yuan, H. X.; Xiong, Y.; Guan, K. L., Nutrient sensing, metabolism, and cell growth control. Mol Cell 2013, 49, (3), 379-87.
  16. Hosokawa, N.; Hara, T.; Kaizuka, T.; Kishi, C.; Takamura, A.; Miura, Y.; Iemura, S.; Natsume, T.; Takehana, K.; Yamada, N.; Guan, J. L.; Oshiro, N.; Mizushima, N., Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009, 20, (7), 1981-91.
  17. Dodd, K. M.; Yang, J.; Shen, M. H.; Sampson, J. R.; Tee, A. R., mTORC1 drives HIF-1a and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 2014, 34, 2239.
  18. Shimobayashi, M.; Hall, M. N., Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nature Reviews Molecular Cell Biology 2014, 15, 155.
  19. Cornu, M.; Albert, V.; Hall, M. N., mTOR in aging, metabolism, and cancer. Current Opinion in Genetics & Development 2013, 23, (1), 53-62.
  20. Vucenik, I.; Stains, J. P., Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci 2012, 1271, 37-43.
  21. Cai, H.; Dong, L. Q.; Liu, F., Recent Advances in Adipose mTOR Signaling and Function: Therapeutic Prospects. Trends Pharmacol Sci 2016, 37, (4), 303-317.
  22. Faes, S.; Demartines, N.; Dormond, O., Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxid Med Cell Longev 2017, 2017, 1726078.
  23. Malley, C. O.; Pidgeon, G. P., The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials. BBA Clin 2016, 5, 29-40.
  24. Roskoski, R., Jr., A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 2015, 100, 1-23.
  25. Benjamin, D.; Colombi, M.; Moroni, C.; Hall, M. N., Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Reviews Drug Discovery 2011, 10, 868.
  26. Rodrik-Outmezguine, V. S.; Okaniwa, M.; Yao, Z.; Novotny, C. J.; McWhirter, C.; Banaji, A.; Won, H.; Wong, W.; Berger, M.; de Stanchina, E.; Barratt, D. G.; Cosulich, S.; Klinowska, T.; Rosen, N.; Shokat, K. M., Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 2016, 534, (7606), 272-6.
  27. Ruiz-Torres, V.; Encinar, J. A.; Herranz-Lopez, M.; Perez-Sanchez, A.; Galiano, V.; Barrajon-Catalan, E.; Micol, V., An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs. Molecules 2017, 22, (7).
  28. Banerjee, P.; Erehman, J.; Gohlke, B. O.; Wilhelm, T.; Preissner, R.; Dunkel, M., Super Natural II--a database of natural products. Nucleic Acids Res 2015, 43, (Database issue), D935-9.
  29. Sterling, T.; Irwin, J. J., ZINC 15--Ligand Discovery for Everyone. J Chem Inf Model 2015, 55, (11), 2324-37.
  30. Bello-Perez, M.; Falco, A.; Galiano, V.; Coll, J.; Perez, L.; Encinar, J. A., Discovery of nonnucleoside inhibitors of polymerase from infectious pancreatic necrosis virus (IPNV). Drug Des Devel Ther 2018, 12, 2337-2359.
  31. Encinar, J. A.; Fernandez-Ballester, G.; Galiano-Ibarra, V.; Micol, V., In silico approach for the discovery of new PPARgamma modulators among plant-derived polyphenols. Drug Des Devel Ther 2015, 9, 5877-95.
  32. Galiano, V.; Garcia-Valtanen, P.; Micol, V.; Encinar, J. A., Looking for inhibitors of the dengue virus NS5 RNA-dependent RNA-polymerase using a molecular docking approach. Drug Des Devel Ther 2016, 10, 3163-3181.
  33. Gilson, M. K.; Liu, T.; Baitaluk, M.; Nicola, G.; Hwang, L.; Chong, J., BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res 2016, 44, (D1), D1045-53.
  34. Guo, Q.; Yu, C.; Zhang, C.; Li, Y.; Wang, T.; Huang, Z.; Wang, X.; Zhou, W.; Li, Y.; Qin, Z.; Wang, C.; Gao, R.; Nie, Y.; Ma, Y.; Shi, Y.; Zheng, J.; Yang, S.; Fan, Y.; Xiang, R., Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer. J Med Chem 2018, 61, (3), 881-904.
  35. Salentin, S.; Schreiber, S.; Haupt, V. J.; Adasme, M. F.; Schroeder, M., PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res 2015, 43, (W1), W443-7.
  36. Rajput, A.; Dominguez San Martin, I.; Rose, R.; Beko, A.; Levea, C.; Sharratt, E.; Mazurchuk, R.; Hoffman, R. M.; Brattain, M. G.; Wang, J., Characterization of HCT116 human colon cancer cells in an orthotopic model. J Surg Res 2008, 147, (2), 276-81.
  37. Cádiz-Gurrea, M. d. l. L.; Olivares-Vicente, M.; Herranz-López, M.; Arraez-Roman, D.; Fernández-Arroyo, S.; Micol, V.; Segura-Carretero, A., Bioassay-guided purification of Lippia citriodora polyphenols with AMPK modulatory activity. Journal of Functional Foods 2018, 46, 514-520.
  38. Nave, B. T.; Ouwens, M.; Withers, D. J.; Alessi, D. R.; Shepherd, P. R., Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999, 344 Pt 2, 427-31.
  39. Peterson, R. T.; Beal, P. A.; Comb, M. J.; Schreiber, S. L., FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 2000, 275, (10), 7416-23.
  40. Edinger, A. L.; Thompson, C. B., Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004, 16, (6), 663-9.
  41. Nicholson, D. W., Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death And Differentiation 1999, 6, 1028.
  42. Jin, L.; Wang, W.; Fang, G., Targeting protein-protein interaction by small molecules. Annu Rev Pharmacol Toxicol 2014, 54, 435-56.
  43. Ivanov, A. A.; Khuri, F. R.; Fu, H., Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci 2013, 34, (7), 393-400.
  44. Pereira, F.; Aires-de-Sousa, J., Computational Methodologies in the Exploration of Marine Natural Product Leads. Mar Drugs 2018, 16, (7).
  45. Nantasenamat, C.; Prachayasittikul, V., Maximizing computational tools for successful drug discovery. Expert Opin Drug Discov 2015, 10, (4), 321-9.
  46. Kapahi, P.; Chen, D.; Rogers, A. N.; Katewa, S. D.; Li, P. W.; Thomas, E. L.; Kockel, L., With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010, 11, (6), 453-65.
  47. Johnson, S. C.; Rabinovitch, P. S.; Kaeberlein, M., mTOR is a key modulator of ageing and age-related disease. Nature 2013, 493, 338.
  48. Sadowski, K.; Kotulska, K.; Jozwiak, S., Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep 2016, 68, (3), 536-42.
  49. Pallet, N.; Legendre, C., Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 2013, 12, (2), 177-86.
  50. Li, J.; Kim, S. G.; Blenis, J., Rapamycin: one drug, many effects. Cell Metab 2014, 19, (3), 373-9.
  51. Neves, J.; Sousa-Victor, P.; Jasper, H., Rejuvenating Strategies for Stem Cell-Based Therapies in Aging. Cell Stem Cell 2017, 20, (2), 161-175.
  52. Weichhart, T., mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review. Gerontology 2018, 64, (2), 127-134.
  53. Ge, D.; Han, L.; Huang, S.; Peng, N.; Wang, P.; Jiang, Z.; Zhao, J.; Su, L.; Zhang, S.; Zhang, Y.; Kung, H.; Zhao, B.; Miao, J., Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy 2014, 10, (6), 957-71.
  54. Peng, N.; Meng, N.; Wang, S.; Zhao, F.; Zhao, J.; Su, L.; Zhang, S.; Zhang, Y.; Zhao, B.; Miao, J., An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E-/- mice. Scientific Reports 2014, 4, 5519.
  55. Bottegoni, G.; Rocchia, W.; Rueda, M.; Abagyan, R.; Cavalli, A., Systematic exploitation of multiple receptor conformations for virtual ligand screening. PLoS One 2011, 6, (5), e18845.
  56. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J., AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009, 30, (16), 2785-91.
  57. Schymkowitz, J.; Borg, J.; Stricher, F.; Nys, R.; Rousseau, F.; Serrano, L., The FoldX web server: an online force field. Nucleic Acids Res 2005, 33, (Web Server issue), W382-8.
  58. Trott, O.; Olson, A. J., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010, 31, (2), 455-61.
  59. Sander, T.; Freyss, J.; von Korff, M.; Rufener, C., DataWarrior: an open-source program for chemistry aware data visualization and analysis. J Chem Inf Model 2015, 55, (2), 460-73.
  60. Cheng, F.; Li, W.; Zhou, Y.; Shen, J.; Wu, Z.; Liu, G.; Lee, P. W.; Tang, Y., admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 2012, 52, (11), 3099-105.